Quick Answer
ORAMED PHARMACEUTICALS INC. reported Stockholders Equity of $199.74 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +36.6% in Stockholders Equity from 2024 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2007 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2008: $4.59 million | Q3 2009: $2.75 million | Q3 2010: $830.3 thousand | Q4 2011: $3.32 million | Q1 2012: $2.40 million | Q2 2012: $1.97 million | Q4 2012: $6.25 million | Q1 2013: $5.25 million | Q2 2013: $4.16 million | Q4 2013: $7.31 million | Q1 2014: $23.33 million | Q2 2014: $21.97 million | Q4 2014: $23.70 million | Q1 2015: $22.34 million | Q2 2015: $21.33 million | Q4 2015: $22.54 million | Q1 2016: $32.71 million | Q2 2016: $30.98 million | Q4 2016: $23.99 million | Q1 2017: $21.32 million | Q2 2017: $19.81 million | Q4 2017: $22.74 million | Q1 2018: $20.48 million | Q2 2018: $16.66 million | Q4 2018: $28.86 million | Q1 2019: $25.35 million | Q2 2019: $21.56 million | Q3 2019: $19.39 million | Q4 2019: $17.16 million | Q1 2020: $16.09 million | Q2 2020: $34.11 million | Q4 2020: $28.21 million | Q1 2021: $49.44 million | Q2 2021: $68.12 million | Q3 2021: $115.77 million | Q4 2021: $170.16 million | Q1 2022: $162.35 million | Q2 2022: $153.70 million | Q3 2022: $153.81 million | Q1 2023: $150.97 million | Q2 2023: $151.55 million | Q3 2023: $149.13 million | Q1 2024: $166.64 million | Q2 2024: $177.07 million | Q3 2024: $156.44 million | Q1 2025: $140.81 million | Q2 2025: $154.53 million | Q3 2025: $203.28 million.
- Over the full 20 years of available data (2007 to 2025), ORAMED PHARMACEUTICALS INC.'s Stockholders Equity has grown by 38,826.5%.
- Historical annual values: Fiscal year 2025: $199.74 million | Fiscal year 2024: $146.27 million | Fiscal year 2023: $163.82 million | Fiscal year 2022: $151.81 million | Fiscal year 2021: $166.45 million | Fiscal year 2021: $115.77 million | Fiscal year 2020: $32.88 million | Fiscal year 2019: $19.39 million | Fiscal year 2018: $31.11 million | Fiscal year 2017: $19.24 million | Fiscal year 2016: $26.19 million | Fiscal year 2015: $24.83 million | Fiscal year 2014: $20.79 million | Fiscal year 2013: $8.13 million | Fiscal year 2012: $3.78 million | Fiscal year 2011: $3.72 million | Fiscal year 2010: $830.3 thousand | Fiscal year 2009: $2.75 million | Fiscal year 2008: $4.59 million | Fiscal year 2007: $513.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: